The mucopolysaccharidoses are a rare group of inherited disorders of connective tissue metabolism characterized by the storage of sulphated mucopolysaccharides (MPS). The phenotypic features are often apparent early in life: dysmorphic or coarse facial features, hirsutism, skeletal abnormalities, joint stiffness and developmental delay. Inheritance is autosomal recessive except for Hunter syndrome which is Xlinked. The first clinical description of patients with MPS diseases was made in 1917 by Charles Hunter.' He described two male siblings with a unique facial appearance (gargoylism), hepatosplenomegaly, short stature, deafness, heart disease and joint stiffness. In 1919 Gertrude H urler? described two unrelated male patients with the same features but with the addition of corneal clouding and mental retardation. These disorders became known as mucopolysaccharidoses in 1952 following the discovery by Brante' of the presence of chondroitin sulphate-like substances stored in the liver and meninges of a Hurler patient.
In 1957 Dorfman and Lorincz" reported increased excretion of MPS or glycosaminoglycans (GAGs) in the urine of patients suffering from a mucopolysaccharidosis. This proved to be of great diagnostic importance and led to the development of urine screening tests for the mucopolysaccharidoses. The type and ratio of the urinary MPS were found to be indicative of the subclass of MPS disease present.
The mucopolysaccharidoses were shown to be lysosomal storage diseases by Van Hoof and This article was prepared under the auspices of the Analytical Investigations Standing Committee of the Association of Clinical Biochemists.
Hers." They were the first to demonstrate large vacuoles containing granular material from the liver of a Hurler patient and suggested that undigested MPS were distending the Iysosomes. Classification of these disorders was standard- used radiolabelled sulphate to compare the kinetics of MPS accumulation in fibroblasts from normal subjects and from patients with Hurler and Hunter disease, to determine whether the problem was excessive synthesis, insufficient degradation or defective secretion of the molecules. They concluded that there was a defect in the degradation of the MPS molecules. When fibroblasts from Hurler and Hunter individuals were mixed, the kinetic pattern of MPS turnover was returned to normal. The effect was mediated by substances or 'corrective factors' released into the culture medium and cell contact was found to be unnecessary. These corrective factors were shown to accelerate the degradation of MPS in recipient cells." The factor which corrected the defect in Hurler cells was found to be produced by all genotypes tested except Hurler. Similarly, the factor which corrected the defect in Hunter cells was produced by all the genotypes teste~except Hunter. This indicated that the defective MPS metabolism was caused by a lack of factors specific for each defect. Cross correction provided a powerful tool in categorizing. the MPS. Neufeld et al. isolated and charactenzed the corrective factors which were enzymes and thereby identified the specific enyme defects in MPS diseases. These are now classified according to the defect (Table I ). The first column of the table refers to the common abbreviation used for each disorder together with the reference number for the classification of the disorders within the catalogue of all inborn errors of metabolism compiled by Victor McKusick. III The catalogue is revised regularly and updated to include current research data. 
THE BIOCHEMISTRY OF MUCOPOLYSACCHARIDES
The MPS are complex molecules consisting of long sulphated polysaccharide chains with up to 100 sugar residues covalently linked to a protein core. In dermatan sulphate, heparan sulphate and the chondroitin sulphates the polysaccharide chains are composed of alternating residues of uronic acid and sulphated hexosamine. Keratan sulphate differs in that it does not contain any uronic acid residues but is composed of alternating residues of galactose and sulphated hexosamine. The structures are illustrated in Fig. I . The polysaccharide chains are bound to specific proteins via a distinct linkage region forming proteoglycans. For the chondroitin sulphates, dermatan sulphate and heparan sulphate, this linkage consists of the sequence serine-xylose-galactose-galactoseglucuronic acid. Several polysaccharide chains are attached to the same polypeptide backbone, with larger proteoglycans forming through noncovalent bonds. Within the carbohydrate chain of any given GAG there is variation in the constituent sugars, degree of sulphation and in the position of the sulphate groups.
The MPS are constituents of connective tissue and the ground substance. They occur primarily in skin, cartilage, bone, blood vessels, heart valves and cornea. They are found in smaller quantities in liver, brain, leucocytes, mast cells and cultured fibroblasts. In the mucopolysaccharidoses, normal large proteoglycans are present in the connective tissue. However, in tissues where abnormal storage occurs, there is also an accumulation of molecules which are much smaller, are of varying length and may be peptide bound. These are also excreted in urine. The linkage region is usually absent suggesting that the cell has tried to cleave as many linkages as possible before stopping at a residue for which the specific degradative enzyme is deficient. This results in the polysaccharide chain being resistant to further cleavage by exoenzymes and thus accumulating in the Iyosomes. In some tissues GAGs can undergo limited degradation by lysosomal endoglycosidases (intrachain cleavage). The incompletely degraded GAG fragments then accumulate in the tissues or are excreted in the urine. An example of the degradative process is illustrated in the stepwise degradation of heparan sulphate shown in Fig.  2 . The deficiency diseases corresponding to the numbered reaction are listed. because of the genetic heterogeneity of the mucopolysaccharidoses.
NORMAL URINARY GAG EXCRETION
In normal adults of the 250 mg of GAGs disposed of daily only 5-10 mg is excreted in the urine. I I The remainder is degraded before being excreted. The principal GAGs normally found are the chondroitin-4 and -6-sulphates, with heparan sulphate (HS) present in small but increasing amounts from adolescence onwards. Urinary GAG excretion varies with age in both health and disease. These age related differences reflect the GAG metabolism in tissue proteoglycans. Concentrations of uronic acid and all bound carbohydrates arc highest in infants and young children when the formation of bone cartilage and other connective tissues are at their peak.I".I' Excretion of urinary GAGs is highest in the first few weeks of life. Age related reference ranges for GAG excretion are dependent on the method used and are given with the method details.
ABNORMAL URINARY GAG EXCRETION
Increased urinary GAG excretion is always found in the mucopolysaccharidoses, In some patients (especially Morquio disease) total urinary GAG excretion is only mildly elevated and can decrease with increasing age. This may reflect both the red uced excretion as a result of the cessation of bone growth and the insensitivity of the analytical methods available. Qualitative analysis of the urinary GAG to demonstrate the excretion pattern is an important part of the diagnostic process as the type of GAG excreted is dependent on the enzyme deficiency. Total quantitative GAG excretion may be increased in other connective tissue disorders, e.g. rickets, rheumatoid arthritis, disseminated lupus erythematosus. The qualitative pattern of GAG excretion in these cases is usually normal.
THE DEVELOPMENT OF METHODOLOGY FOR THE QUANTITATIVE AND QUALITATIVE ASSAY OF GAG
Early experiments showed that the direct chemical estimation of M PS by the measurement of hexuronic acid content was not possible due to the presence of other hexuronic acid containing substances in urine. A variety of methods was developed to separate the urinary GAGs from these interfering substances including dialysis but this was unreliable because the amount of hexuronic acid-containing material present after dialysis varied with the duration of the procedure, the number of changes of distilled water and the pore size of the membrane. Considerable losses of GAG sometimes occurred using this purification method.
Other isolation techniques utilized the polyanionic nature of GAGs including: Precipitation using solutions of quaternary ammonium salts, e.g, cetyl ammonium
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bromide (CTAB) or cetyl pyridinium chloride (CPC)14 2 Retention on, and selective elution from, anion exchange resins with appropriate salt solutions. IS These methods were found to be suitable for the measurement of high molecular weight GAGs but were inadequate for the measurement of low molecular weight hexuronic acid-containing anionic compounds, considered to be degradation products of GAG metabolism. The measurement of both the 'degradation products' and the high molecular weight GAGs was achieved by DiFerrante et al. in 1971. 16 The total urinary GAG was precipitated using CPC (10% w]» solution). After centrifugation at 4"C, the CPC precipitates were washed with potassium acetate in ethanol and then dissolved in water. Sodium chloride solution was added to the aqueous solutions to precipitate the urinary glycoprotein. After centrifugation the CPC was removed from the supernatants by passing them through Dowex columns and eluting with sodium chloride of increasing molarity. Each fraction was then analysed for iduronic acid and 2-deoxy-2-sulphoaminohexose using gas liquid chromatography (GLC). Following the isolation of the urinary GAG from the appropriate fraction, the hexuronic acid content was assayed using the borate modification of the carbazolesulphuric acid reaction as described by Bitter and Muir.!'
CHEMICAL MEASUREMENT OF HEXURONIC ACID
The first assay for GAGs The original method was developed by Dische lg for the assay of the hexuronic acid moieties of the GAG chains. This method is a direct chemical reaction of the uronic acid in the GAG chains. It is simple to perform but has the disadvantage of using a reagent containing concentrated sulphuric acid and thus presents a safety hazard. Uronic acids react with carbazole in the presence of borate in a strongly acid solution to form a magenta coloured product which can be quantified. It can be used for analysis of all the GAGs except for keratan sulphate which does not contain any uronic acid. GAGs are first separated from other interfering substances in urine using CPC preciptiation as described above. The precipitated GAGs are dissolved in deionized water and then carefully 2. Upper limits of reference range for urinary excretion of hexuronic acid according to a/(e in histochemical and cytochemical studies and has been applied to urine screening methods in spot tests, precipitation and spectrophotometric assays.
Spot tests
In these tests a fixed volume of urine is applied to filter paper, dried and stained with a solution of an appropriate dye. Although simple to perform, false positive and negative results occur frequently. Simple spot tests based on the metachromasia of toluidine blue were introduced by Berry and Spranger." An alcian blue spot test was developed by Carson and Nei1l 22 but this test was found to give positive results in 25% of all normal children tested. In a study of the Ames MPS paper spot test (based on Azure A dye) by de long et al.,23 76 urine samples (48 normals and 28 from MPS patients) were dispatched to three different laboratories currently using the test. False negative results ranged from 19-35%, and false positive results from 12-29% of all samples submitted. Sensitivity and specificity varied among the laboratories involved. The best results achieved were 81% sensitivity and 88% specificity. The test was improved by spotting a urine volume containing a known amount of creatinine to allow for urine concentration, but this still did not eliminate false negative results. These tests are still used in some laboratories in spite of their inaccuracy and their inability to take age related changes in GAG excretion into account. 212 Stone layered on top of the sulphuric acid/borate reagent in pyrex test tubes. The contents of the tubes are mixed with constant cooling as the reaction is very exothermic and the temperature can rise to 135°C at the interface if cooling is omitted. The tubes are heated for 10mins in a bath of vigorously boiling distilled water and then cooled to room temperature in cold water. Carbazole reagent is added and the tubes heated again in a boiling water bath. After cooling to room temperature the absorbance is measured at 530 nm. Contamination of the samples by dust or chlorinated water results in oxidant formation producing a green colouration which interferes with the formation of the magenta coloured product. The original method recommends that the reagent is cooled to -70°C before adding the sample, with the tubes being allowed to warm to room temperature during the mixing. The method is sensitive to 1 mg/L of uronic acid but reproducibility below 4mg/L is poor. Glucuronolactone is used as the standard and the reaction is linear between 4 mg/L and 40 mg/L glucuronolactone. Within-batch imprecision (coefficient of variation) was 4.8% for an aqueous solution of 50 mg/L of chondroitin sulphate with a uronic acid content of 16·5 mgj' L. 19 Age related reference ranges should be established for all methods for the estimation of urinary GAGs. Table 2 shows the upper limit of the reference range (based on a study of 2000 infants, of whom 160 were neonates), for GAG hexuronic acid in relation to creatinine."? These early methods of quantification of urinary GAG concentration after removal of interfering materials in the urine are useful only in the research laboratory as reference methods They have been superseded by the development of simpler assays that are more readily adaptable as screening tests.
Screening tests
Early attempts by Dorfman/? to produce a screening test were based on an assay procedure for hyaluronidase activity involving precipitation of GAG with acidified bovine albumin. This test was found to be unreliable and false negative results were produced in patients with Hurler syndrome and Sanfilippo syndrome. GAGs interact with a number of basic dyes, e.g. toluidine blue, a1cian blue, methylene blue, acridine orange and rithemium red to form insoluble precipitates. This reaction forms the basis for the detection and localization of GAGs 
"Results higher than this may be found In normal infants in the first 2 weeks of life. before the Cl'C assay is performed. Both samples and standards must be allowed to come to room temperature (20 0 -2 5°C ) before starting the assay because Cl'C precipitates at low temperature giving a falsely high turbidity. The sample is mixed with Cf'C in citrate buffer pH 4·8. A blank is set up for each test in which the sample is mixed with citrate buffer only. The tubes are left to stand for 30 min and then remixed. The absorbances of the blanks, tests and standards are then read at 680 nm. The absorbance is linear up to a concentration of 100 mg/L, The results are calculated in Cl'C units---one Cf'C unit is equivalent to the absorbance given by 1 mg/L of GAG under the conditions of the test. The results are not expressed directly in mg because different GAGs give slightly different turbidity readings at the same solution concentration.The results are finally expressed as epe units/mol creatinine. Age related cut off values should be defined by the individual laboratory using the assay. Published reference ranges from other laboratories for each method can be used as a guide. The range used in our laboratory for the Cf'C assay is given in Table 3 .
Precipitation tests
The observation by Scott-" that GAGs will react with quaternary ammonium compounds to form a precipitate was used as the basis for a screening test by Renaurt." This method described the reaction of GAG with eTAB to form a flocculent precipitate. However, the test was difficult to interpret because normal urine often gave a peculiar precipitate and a true flocculent precipitate was rarely seen. It was therefore not adopted as a screening test. The screening test described by Manley and Hawksworth-" measured the turbidity produced by reaction or urinary GAGs with the detergent Cl'C, However, timing was a critical factor in the assay because the formed particles aggregated after 4 min, making the original assay unsuitable as a simple screening test. Scott?" subsequently showed that precipitation of GAG with Cf'C is affected by both pH and urine concentration. The possibility of false positive and false negative results can be reduced by taking these factors into account. Modification of the epe assay, by the introduction of citrate buffer pH 4·8 by Pennock et al. 2x overcame the effects of changes in pH and ionic strength, and stabilized the precipitate. This reduced the critical time dependence of the original assay described by Manley and Hawksworth. The results were quantified by the introduction of chondroitin sulphate standards and urine concentration was taken into account by relating the results to the urine creatinine concentration. These modifications resulted in a quantitative assay suitable for use as a screening test on random urine samples. A study of 3000 children gave an incidence of false positive results of 5% in the first year of life and 2·6 in older children-? which was considered acceptable. No false negative results were found. Between batch imprecision (coefficient of variation) for chondroitin sulphate solutions containing 44·7mg/L and 100mg/L were 7-4% and 5·7% respectively."
The epe citrate assay is stil1 one of the most commonly used screening tests for MPS disease. A disadvantage is that it cannot be used for dilute urines with a creatinine of less than 1 mrnol/L which is a problem with samples from babies and young children. Samples giving results greater than the top standard cannot be diluted to give an accurate GAG concentration, but these samples should aways be investigated further to identify the individual GAG components. The urine samples should be centrifuged reaction of the alcian blue with the urinary GAGs. The alcian blue assay measures GAGs by their polyanionic nature rather than the constituent groups in the back bone chain. The advantage of this method over the Cf'C citrate method is that the colour yield for equal amounts of different GAGs is almost identical. It can also be used to quantify keratan sulphate which does not contain any uronic acid and cannot be quantitated chemically using the reaction of Bitter and Muir. 17 The number of samples that can be analysed in one batch is determined by the number of tubes that can be accommodated in the centrifuge at anyone time. A series of duplicate determinations on 10 urine samples gave an average coefficient of variation of 2·7%. Results using the alcian blue method tend to be slightly higher than those obtained by measuring Cl'C precipitable hexuronic acid. This may be due to binding of the dye by anions present in the urine. DNA and RNA form complexes with alcian blue under the described assay conditions but give lower absorption readings than an equal weight of chondroitin-4sulphatc.F However, it is unlikely that these substances would be present in sufficient quantities in centrifuged urine to affect the assay of urinary GAG. Other negatively charged molecules, e.g. amino acids have also been found to interfere in this reaction. The age related reference range commonly used for this method is shown in Table 4 . The alcian blue assay can be used on samples that have been diluted and therefore gives a more accurate result with high GAG concentrations than the CPC citrate assay.
Stone
Spectrophotometric tests based on the reaction of the GAG with dyes These tests are based on the reaction of the polyanionic GAGs with a positively charged basic dye to form a coloured complex. When both the basic dye and an uncoloured cation are present together in solution there is competition between the dye and the cation for the anionic sites on the GAG. At the critical electrolyte concentration all the bound dye is released and can be measured.
Alcian blue
Scott et al. showed that under controlled conditions, the cationic dye alcian blue 8GX formed insoluble complexes with acid GAGs. 30 Further studies confirmed the critical electrolyte concentrations for the interaction of the alcian blue with polyanions. 3 1 Whiteman described a quantitative assay for urinary GAGs using alcian blue'? which is now widely used as a screening test. The assay involves the direct reaction of urine with reagent containing 0·05% (w/v) alcian blue and 50 mmol/L magnesium chloride in 50 rnrnol/L sodium acetate (adjusted to pH 5·8 with acetic acid). After equilibration at room temperature for 2 h the alcian blue-GAG complex is separated by centrifugation at 2000 g for IS min. The precipitate is then washed with ethanol and centrifuged as before. This is followed by dissociation of the complex with water or with the ionic surfactant Manoxol B solution. The absorbance of the resulting clear blue solution is measured at 620 nm and is directly related to the concentration of urinary GAG. Chondroitin sulphate is used as the standard. At concentrations less than 20 mg/L the limit of the method is reached, and a repeat sample must be requested. The reaction is linear up to a GAG concentration of 100mg/L. As with the CPC reaction this test is not reliable when the urine creatinine is less than I mmol/L. 28 where GAGs are precipitated before the borate/carbazole reaction showed a linear correlation. The use of OMB dye therefore provides a suitable alternative to the chemical measurement of the hexuronic acid moieties which is hazardous to perform because of the use of concentrated sulphuric acid in the reagents. A disadvantage of this method is the initial precipitation steps. This was overcome by Whitley et al. and de long et al. '7,'8 who described the direct assay of urinary GAGs using OMB dye. The method is simple to perform and involves mixing 100 ilL of urine or standard with 2'5mL of working dye solution at pH 3·5. The absorbance of the resulting GAG-dye complex at 525 nm is stable after 6 min. Chondroitin sulphate is used as the standard and the reaction is linear up to a concentration of 120 mg chondroitin sulphate/L, It is ideally suited for automation for the analysis of large numbers of samples in a screening programme. The age related reference range used in our laboratory is shown in Table  5 . A critical factor in the assay is the purity of the OMB dye and it has been shown that using an impure dye can lead to false negative results." In the manufacturing process the dye can become contaminated by excess sulphur. This results in a reduction of the binding sites available for the negatively charged sulphate and carboxyl ions on the GAG chains leaving unreacted GAG in solution.l" The purity of the dye can be checked by calculating the ratio of the absorbance of the dye at 647 and 595 nm-a minimum ratio of > I : 1·3 is required for accurate results. 3D Unreacted OMB dye solution has absorbance peaks at 595 nm and 647 nm. Reaction of the dye with GAG results in the formation of a coloured complex with a maximum absorbance which varies with GAG The volume of urine required for this assay is only 50 ul, which is an advantage when urine collection is difficult from young children. A disadvantage of this method is that the alcian blue-GAG precipitate is very finely dispersed and is often difficult to harvest. This can lead to loss of the precipitate and inaccurate results when the reaction is carried out by inexperienced staff.
1,9-Dimethylmethylene blue
Dimethylmethylene blue (OMB) was first described as a sensitive histochemical stain for the induction of metachromasia by Taylor and Jcffrce. " The dye was subsequently applied to a colorimetric assay for sulphated GAGs in tissues by Humbel and Etringer.I" OMB dye is one of the most sensitive thiazine compounds giving a marked absorbance shift when complexed with GAG. The assay described by Humbel and Etringer had the disadvantage that the reagent used was unstable and the sulphated GAG-dye complexes tended to precipitate during the assay. Farndale et a/.'s overcame these problems in the micro assay of sulphated GAGs in cartilage cultures by replacing the citrate/phosphate buffer with formate.
The use of OM B dye in the assay of sulphated GAGs was adapted for use on CPC-precipitated urinary GAGs by Panin et al. '6 The pellet was resuspended in deionized water and O'5 mL of the suspension was reacted directly with 2·5 mL of OMB dye reagent (l6mg OMB dye, 5mL ethanol, 2 g sodium formate and 2 mL formic acid diluted to 1·5 L with deionized water). The absorbance was read after 5 min at 535 nm using disposable plastic cuvettes. Care was taken to restrict the GAG assay to concentrations within the linear range of the assay by taking appropriate aliquots of the precipitated GAGs in the same final volume ofO·5mL. The reaction was found to be linear up to 120 rng/L, The colour was stable after 5 min and for up to 20 min. Aqueous solutions of chondroitin sulphate were used as standards. The GAG excretion was calculated as mg GAG/24 hand all assays were performed in triplicate. Within batch imprecision calculated from 20 replicate analyses of three 24-h urine collections with mean GAG contents of 2-4, 62·1 and 175·3 mgyl, GAG were 2·5%, 1·6% and 2·1 %, respectively. Between batch imprecision ranged from 1,8-4·5%. The linearity of the method showed that only pathological samples would require dilution. A comparison of the OMB method with Stone species from 525 nm for chondroitin sulphate to 535 nm for keratan sulphate. At low GAG concentrations the coloured complex produces a broad peak resulting in inaccurate measurement of the GAG concentration. The assay is sensitive for GAGs and in a field trial carried out from our laboratory using 600 urine samples only one false negative result was found. This was from a 29-year-old patient with MPS IV (Morquio disease) and it is known that patients with this disease do not always excrete detectable levels of keratan sulphate after puberty. There was a small incidence of false positive results of 0.8%. As de long et al. showed, the dye also reacts with other negatively charged particles in urine including urine proteins/" Urinary GAG concentrations measured by this method were found to decrease significantly with increasing urinary protein concentration. This may lead to false negative results. To minimize the protein effect de long et al. modified the procedure by changing the ionic strength (3l/lol/L to l80/lmol/L) and pH (3'5-8'8) of the working dye solution.f Under the acidic conditions of the original method basic groups in protein become positively charged and react with the GAG so inhibiting the reaction of the GAG with the positively charged dye. At pH 8·8, most urinary proteins are negatively charged and will not bind to the GAGs. However, there may be interference at this pH by polyanions, e.g. DNA, RNA and hyaluronic acid. This problem of protein interference was not observed by Whitley et alY using albumin at concentrations found in urine. The only interfering substances they reported were heparin (likely to be found only in the neonatal unit), and drugs containing artificial colouring agents, e.g. erythromycin and ethyl succinate.
THE QUALITATIVE ANALYSIS OF URINARY GLYCOSAMINOGLYCANS
The quantitative detection of abnormal urinary GAG excretion suggests the presence of MPS disease. The qualitative identification of the individual GAG molecules and their relative proportions is an important indication of the enzyme defect. The qualitative analysis of the urine from these patients is an essential stage in the diagnostic process by directing the path of the enzymatic evaluation of the diagnosis which is costly and technically more difficult. In MPS I and MPS II dermatan sulphate is excreted in Ann cu« Biochem 1998: 35 approximately equal amounts with heparan sulphate. Heparan sulphate is excreted in MPS III and keratan sulphate in MPS IV. In MPS VI only dermatan sulphate is excreted but in MPS VII dermatan sulphate is excreted with heparan sulphate, chondroitin-4 and chondroitin-6-sulphates. MPS I and II cannot be distinguished from each other by examination of the urinary GAG excretion patterns (see Table I ).
Methods for the identification of urinary GAGs Identification of the GAG excretion pattern requires simple methods for the separation and assessment of the relative proportions of the individual GAGs. The initial step is the isolation of the urinary GAGs using CPC or alcian blue as previously described. Other methods for the isolation of the GAGs include ultrafiltration of the urine under nitrogen, followed by preparative gel filtration to isolate the fraction containing the GAGS. 4 1 Identification of the GAGs can then be achieved using a chromatographic system, e.g. column or thin layer chromatography (TLC) or by electrophoresis.
Chromatographic separation of glycosaminoglycans
Column chromatography Column chromatography has been extensively used as a research tool in the separation of urinary GAG mixtures. It is not applicable to the diagnostic laboratory and the separations achieved are often imperfect.F Separation of dermatan and heparan sulphates requires pretreatment with an alkaline copper reagent followed by hydrolysis. Analysis of the amino sugars requires another column chromatographic procedure to separate the glucosamine and galactosamine portions of the molecules.
High-performance liquid chromatography and GLC Kodama et al. showed that analysis using highperformance liquid chromatography (HPLC) may be useful in the differential diagnosis of MPS disorders.P The method involves derivatization of the saccharides by reductive deamination prior to HPLC analysis. Several enzymic digestions of the urinary GAGs were performed including pronase, chondroitin ABC lyase, chondroitin-4-sulphatase, chondroitin-6-sulphatase and fJ-glucoronidase. Chondroitin sulphates A and C were digested separately with testicular hyaluronidase. These enzymic digests were However, the GAGs excreted in MPS diseases do not always have the same R F values as pure standards causing difficulty in the interpretation of the chromatograms. Heparan sulphate in urine from patients with MPS II has a similar R F value to that of heparan sulphate standard but in patients with MPS III the heparan sulphate migrates in a similar position to that of chondroitin-6-sulphate. This may result in a missed diagnosis of MPS III. As illustrated in Fig. 3 the pattern may appear to be normal as to the inexperienced eye. Incomplete separation of keratan sulphate from chondroitin-6-sulphate may result in the failure to diagnose MPS IV. This problem was solved in our own laboratory by increasing the concentration of ethanol in the first solvent to 70% (C A Pennock, personal communication). A quality assurance exercise for urinary GAG excretion highlighted difficulties in the determination of qualitative GAG excretion patterns in MPS disease using TLC48 which could lead to the misdiagnosis of MPS III as MPS I or MPS II. Chondroitin sulphate can be readily distinguished from other GAGs by its susceptibility to enzymic digestion with hyaluronidase or chondroitinase AC. Overnight incubation at 37"C with a solution of I mg/ml. enzyme (in O·IM sodium acetate buffer pH 4·7 containing O·IM sodium chloride) results in total digestion of the chondroitin sulphate leaving the heparan sulphate, dermatan sulphate and keratan sulphate in solution. The samples can then be reanalysed by TLC. Some samples contain material which remains at the application line of the chromatogram and causes distortion of the GAG pattern. This effect can be overcome' by adding the GAG supernatant dropwise to I mL of a 10% solution of potassium acetate in ethanol. The solutions are then mixed well and left to stand overnight at 1st-2nd 10-20 2nd-3rd 20-30 3rd--4th 30--40 4th-5th 40-50 5th-6th 50-60 With the 60 solvent front lyophylized and converted into fluorescent pyridylamino derivatives for HPLC analysis. The results showed that dermatan sulphates excreted in MPS I and MPS II are different reflecting the different enzyme defects. Similarly chromatograms of the pyridylamino derivatives of the chondroitin ABC lyase of urinary GAGs from patients with MPS 1Il differed significantly from those of other MPS disorders illustrating that the heparin sulphate excreted in MPS III is different from that excreted in other MPS disorders. This is demonstrated with other separation techniques as will be described later. Separation of GAGs by HPLC is complex to perform and is only suitable as a research tool.
GLC method for the separation of acetylated derivatives of reduced glucosamine and galactosamine fractions of GAGs excreted in MPS diseases was described by Murphy et a/. 44 Isolation of GAGs from urine using CPC was followed by acid hydrolysis and reduction using borohydride. The samples were then acetylated and analysed by GLC. Galactosamine and glucosamine derived from dermatan sulphate and heparan sulphate, respectively, can be separated using this system, and it is therefore useful in distinguishing MPS III from MPS I and MPS II. This method is also complex to perform and not suitable for routine diagnostic use.
Thin layer chromatography TLC has been widely used in GAG analysis. Initially, difficulties were experienced in the separation of dermatan sulphate and keratan sulphate from other GAGs. 4 5 The best separation is achieved by utilization of the differences in relative solubilities of the calcium salts of GAGs in different concentrations of ethanol. This was initially applied to tissue GAGs by Lipiello and Mankin 46 and modified for urinary GAGs by Humbel and Chamoles."? In this system the GAGs are chromatographed through six solvents containing increasing volumes of acetic acid (containing calcium acetate) and decreasing volumes of ethanol. After drying in hot air the chromatogram is stained with toluidine blue. Excess stain is removed by washing with 10% acetic acid solution and the chromatograms are dried. Dermatan sulphate was found to be the GAG with the slowest migration and keratan sulphate the fastest. The variation in the R F values for the individual GAGs with the ethanol concentration in the solvent system is illustrated in Table 6 . dcrrnatan sulphate and heparan sulphate hut chondroitin sulphate and kennan sulphate migrate at the same rate as illustrated in Fig.  4 . The barbitone buffer system'" utilizes sodium barbitone.sodium acetate buffer pH l)'2 and separates the GAGs according to their amino sugar components. The method is similar to that using barium acetate buffer hut the time of the electrophoresis is reduced to 20 min. Dermatan sulphate migrates with the chondroitin sulphatcs and hcparan sulphate with keratan sulphate. A mixture of pyridine acetic acid water (10: I : Xl) by volume) facilitates good separation of chondroitin sulphate. heparan sulphate and kcratan sulphate hut derma tan sulphate migrates with chondroitin sulphate (A Cooper. personal communication). Keratan sulphate and chondroitin sulphate may be distinguished using SOmmoLL lithium chloride and IOmmol L EDTA.
Two-dimensional C/CI'trtJp/IImsis
Two-dimensional (2-D) electrophoresis facilitates the specific separation of all GAGs by the utilization of their migration properties within two different solvent systems. The I-D systems described above can be combined in several ways. The best combination has been found to be: 
Sample quality and collection
Ideally the excretion of GAG in a 24 h period should be measured. However, collection of 24 h urine samples from young children is usually difficult. Screening tests are therefore performed on random urine samples and the results related to the excretion of creatinine. Although the excretion of creatinine varies during a 24 h period and the GAG/creatinine ratio is increased at night,54 the excretion of both substances remains fairly constant during waking hours. GAG/creatinine ratios in random samples have been found to be similar to those obtained on complete 24 h collections. 54 A random urine (2 m l.) is sufficient for the screening tests described above. The identification of the urinary GAG excretion pattern requires a 5 rnl, random urine sample for precipitation of the urinary GAG prior to the qualitative analysis. Therefore, 7 mL is required for full investigation. Urine can be collected into plain bottles and should be stored frozen at -20"C until assayed. The samples may be transported by first class post to a tertiary referral centre for assay and do not require to be transported in the frozen state. The presence of bacterial growth in the urine samples may give anomalous results. Bacteria may produce GAGs causing false positive results (unpublished observations from our own laboratory), or they may degrade GAGs causing false negative results.V' Cloudy smelly samples should therefore not be analysed, and a repeat sample requested. Thiomcrsal may be used as a preservative but is not usually considered to be necessary. Some urine samples may be very concentrated which can lead to error in quantitative
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analysis, because of inadequate isolation of the GAG,56 or underestimation of the GAG content when a direct dye-binding method is used. Very dilute samples of low specific gravity and creatinine content should be discarded since small errors in the estimation of creatinine can lead to false negative or false positive results.
INTERNAL QUALITY CONTROL AND EXTERNAL QUALITY ASSESSMENT
There are no commercially available quality control samples for the assay of urinary GAGs. Standard practice for internal quality control of quantitative assays is to use a normal (i.e. non-MPS) urine sample, stored at -20°C in aliquots and assayed with each batch. A repeat sample from the previous batch should also be assayed. Quality assurance of qualitative assays is achieved using pure GAG standard mixtures, urine GAG samples precipitated from normal urine (negative controls) and urine GAG samples precipitated from known MPS patients (positive controls). Quality assurance of the enzymic digestion of chondroitin sulphatcs is performed by setting up the digestion using pure chondroitin sulphates in parallel with that of the urinary GAGs precipitated from the test and comparing the urine GAG patterns obtained with either TLC or electrophoresis. An external quality assessment exercise for urinary GAG excretion was set up in Bristol" following concerns expressed by parents at an annual conference of the MPS Society in 1990. Urine samples collected from four MPS patients and two non-MPS patients were distributed to 33 laboratories. Seven national reference laboratories assigned the correct diagnosis to all samples analysed. Qualitative turbidity and spot tests were shown to be unreliable. Detection of keratan sulphate was problematic using only 1-D electrophoresis and with a TLC system using the original method of Lipiello and Mankin'" rather than the modification of Humbel and Chamoles." 2-D electrophoresis was shown to be the preferred method provided that staff had adequate interpretative experience. Clinically unacceptable delays in analysis were common with 80% of laboratories taking longer than 10 days to issue a report. This scheme was disbanded because of difficulties in obtaining the required volumes of authentic urine samples. External quality assurance of many tests related to the diagnosis of inherited metabolic 57 The participants in the scheme range from those laboratories performing 1-10 tests per year to those performing > 250 tests per year. All the methods described in this review are used by one or more of the participating laboratories. A comparison of the results has been made although the scoring of the data was complicated by the diverse number and type of methods being performed. A simple assessment was made based on two points being given for a correct result, one point for partially correct and no points for an incorrect result. The scores were expressed as a percentage of the total maximum available and are shown in Table 7 . These results illustrate the inaccuracies of all the screening methods when used in isolation. Inclusion of qualitative assays is therefore essential when there is strong clinical suspicion of an MPS disorder. Confirmation of the enzyme deficiency in leucocytes or fibroblasts is necessary to complete the diagnosis.
COMPARATIVE COSTINGS
The cost of reagents per test is small and is similar for each of the individual assays. The Ann eli" Biochem 1998: 35 equipment used is also comparable between assays. The major contributing factor to the cost is the technical time involved as illustrated in 
CONCLUSIONS AND RECOMMENDATIONS
Simple spot tests are unreliable because they are based on the measurement of the GAG concentration and not the relative GAG excretion-they do not take the creatinine concentration into account. Spot tests can give false negative results and their use in screening for MPS disorders should be discontinued. Quantitative tests taking the urine creatinine concentration and the age of the patient into account reduce the incidence of both false negative and false positive results. These tests include simple screening tests involving direct reaction with the urine and methods in which the urinary GAGs are purified using precipitation techniques before analysis.
The CPC screening test with the modifications made by Pennock et al. 19 to stabilize the precipitate is reliable but requires careful attention to detail. No false negative results have been found using this assay when used on undiluted samples as stated in the original method, but it has a small rate of false positive results. The harvesting of the finely dispersed blue precipitate in the alcian blue method is difficult to achieve. This can lead to underestimation of the GAG concentration. This method encompasses an equilibration time with the dye of at least 2h followed by a 30 min centrifugation of the precipitate. The procedure is therefore not as readily adaptable as a screening test as the other methods described.
DMB can be used in direct reaction with urine or indirectly on precipitated GAGs. Used directly on urine it is simpler than both the CPC citrate and alcian blue assays. When used on precipitated GAGs (more accurate as interfering substances have been removed) it provides a reliable alternative to the chemical measurement of the hexuronic moieties using the borate/ sulphate reaction modified by Bitter and Muir.!?
The use of the DMB dye has the following advantages over the original carbazole reaction:
Reagents are less hazardous-an important consideration for the Control of Substances Hazardous to Health regulations 2 The assay takes less technician time to perform and is therefore cheaper 3 The dye reacts with keratan sulphate and can be used for the detection of all MPS disorders
The DMB reaction should be treated with caution as the manufactured dye is often impure which can result in underestimation of the GAG concentration. This could result in an apparently normal screening result from an affected child. This is especially important in the cases of Sanfilippo syndrome where there are very few (if any) clinical indications of MPS disease in the first few years of the patient's life. The absorbance of the working dye solution should be checked before use and the dilution adjusted to give a ratio of absorbance of the solution at 647 nm: 595 nm of greater than I: 1·3. The manufacturers of the dye need to be made more aware of the requirement for pure dye for this type of quantitative assay.
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The choice of method for use as a screening test is dependent on the simplicity, reliability, cost and time taken to perform the test. An extensive study of the direct DMB assay undertaken in our laboratory has shown that this is the simplest and fastest to perform and unlike other methods has the potential of automated analysis.
The method of choice for the qualitative analysis of urinary GAGs depends greatly on the experience of the operator. 2-D electrophoresis facilitates separation of all the GAGs but is difficult to interpret without experience. TLC using the modifications published by Humbel and Charnoles'" also allows complete separation of the individual GAGs. However, with this system the HS excreted in MPS III shows different characteristics to that of the HS marker and can be mistaken for chondroitin sulphate. This can result in missed diagnosis of this syndrome. Discontinuous electrophoresis is easier to interpret than the 2-D system and can distinguish MPS III from MPS I and II.
In summary, the most common quantitative procedures currently in use in the UK are the CPC-citrate and the direct reaction with DMB dye. Qualitative methods in popular use are I-D and 2-D electrophoresis. Discontinuous electrophoresis is technically more complex but provides the best resolution of urinary GAGs. The most important criterion in the choice of qualitative method is the experience of the operator. The differences between the methods are small with the key factor being the interpretation of the results.
If there is any clinical suspicion of an MPS disorder the urine sample must be fully investigated both quantitatively and qualitatively to ensure that a diagnosis is not missed. Qualitative analysis of the urine is very important as in some patients the quantitative GAG excretion is only marginally elevated. Identification of the specific enzyme defect in either leucocytes or fibroblasts in a specialist centre provides the definitive diagnosis.
